The art of deception:An analysis of social engineering tacticsin financial fraud
Is this your thesis?
This record came from a bulk archive import. If it’s yours, link it to your profile.
Abstract (EN)
Social engineering is a deceptive tactic used by fraudsters to manipulate individuals into divulging sensitive information or performing actions that are against their best interests. It involves exploiting human psychology and emotions to gain trust and access to confidential information, systems or assets. This paper discusses the different types of social engineering techniques used in fraud, including phishing, pretexting, baiting, and so on. It also examines the impact of social engineering on individuals and the measures that can be taken to prevent or mitigate its effects. By understanding the psychology behind social engineering, individuals can better protect themselves from the negative consequences of these tactics, which can range from identity theft and financial loss to reputational damage and legal liability. Key Words: Fraud, financial fraud, fraud prevention methods, identity theft, social engineering
Author
Nida Engin
Institution
How to Cite
Nida Engin (Master Thesis). The art of deception:An analysis of social engineering tacticsin financial fraud, 2024, Yeditepe University.
Keywords
License
Tüm Hakları Saklıdır
This work is shared under the specified license terms.
More theses from Yeditepe University
- Studies on cyclodextrin complexation of a poorly water soluble anti-hyperlipidemic drug, tablet formulation and characterization(2021)
- Washington ambassadors in Turkish-US relations (1927-1960)(2023)
- Metamorphosis of female voices: A study of the violation of women in Greek and Roman mythology and feminist rewritings reclaiming the narrative(2022)
- Knowledge distillation with foundation models for image segmentation(2023)
- The relationship between machiavelism, grandiose and vulnerable narcissism, and loneliness among white collar workers(2023)
- Evaluation of drug-drug interaction checkers along clinically relevant adverse drug events in oncology and hematology pediatric patients(2023)